Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments

PCOS Challenge, a patient advocacy organization, supports the FDA's Patient-Focused Drug Development (PFDD) meetings. They argue that these meetings create durable structural changes by organizing patient communities, identifying critical research gaps, and providing a reusable evidence base for developers and clinicians to align drug development with patient-defined priorities.

The Critical Path Institute (C-Path), a nonprofit organization, supports the FDA's initiative on patient-focused drug development (PFDD) meetings. They provide detailed examples of how these meetings have identified scientific gaps, informed clinical trial designs, and improved patient engagement for conditions like Polycystic Kidney Disease and Alpha-1 Antitrypsin Deficiency.

BioMarin Pharmaceutical Inc. supports the FDA's efforts regarding Patient-Focused Drug Development (PFDD) meetings, noting their role in improving stakeholder engagement and clinical trial design. The company advocates for greater transparency from the FDA regarding how patient experience data specifically informs regulatory decision-making.

The National Eczema Association (NEA) supports the FDA's request for information on Patient-Focused Drug Development (PFDD) meetings, highlighting how past meetings have informed their research and advocacy. They recommend establishing a transparent follow-up process for Voice of the Patient Reports and creating a publicly available compendium of collective learnings from all PFDD meetings.

The Biotechnology Innovation Organization (BIO) supports the FDA's initiative regarding Patient-Focused Drug Development (PFDD) meetings, highlighting how they provide valuable insights into patient experiences and disease burdens. They argue that these meetings foster collaboration, inform clinical trial designs, and create enduring resources that improve patient-centered drug development.

The FSHD Society, an advocacy and research organization for facioscapulohumeral muscular dystrophy, supports the FDA's request for information on patient-focused drug development (PFDD) meetings. They highlight the success of their own "Voice of the Patient" report and urge the FDA to issue guidance on how rare disease organizations can continue to collect, update, and share patient preference data with the agency.

Tanya Stevenson, CEO of the Myotonic Dystrophy Foundation, supports the FDA's efforts to improve the patient-focused drug development (PFDD) process. She emphasizes the importance of incorporating patient preference data and first-hand experiences into the drug development pipeline for rare diseases like myotonic dystrophy.

The Lupus Foundation of America supports the FDA's initiative to document the impacts of Patient-Focused Drug Development (PFDD) meetings. The organization provides detailed examples of how a past lupus PFDD meeting influenced research priorities, advocacy strategies, clinical practice, and healthcare decision-making.

MitoAction, a national patient advocacy organization, supports the FDA's Patient-Focused Drug Development (PFDD) meetings and highlights their success in establishing a shared understanding of mitochondrial disease burden. They argue that these meetings should serve as the start of an ongoing partnership with the FDA to ensure patient experience data evolves alongside scientific discoveries.

Otsuka Pharmaceutical Development & Commercialization, Inc. supports the FDA's initiative to understand the impacts of patient-focused drug development (PFDD) meetings. The company provides specific examples of how these meetings have helped identify unmet needs, inform research initiatives, and shape conceptual frameworks for diseases like PKU, schizophrenia, and IgA nephropathy.